H.R. 2113 · 115th Congress
Speeding Access to Already Approved Pharmaceuticals Act of 2017
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 115th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
StiversSponsor
Speeding Access to Already Approved Pharmaceuticals Act of 2017
What it does: CRS summary · Introduced in House · Apr 20, 2017
Speeding Access to Already Approved Pharmaceuticals Act of 2017
This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration to facilitate the development and expedite the review of a new drug, biological product, or medical device that has been approved in the European Union.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Speeding Access to Already Approved Pharmaceuticals Act of 2017
Latest action (Apr 21, 2017): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Apr 20, 2017
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.